MA56286B1 - Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r? - Google Patents

Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r?

Info

Publication number
MA56286B1
MA56286B1 MA56286A MA56286A MA56286B1 MA 56286 B1 MA56286 B1 MA 56286B1 MA 56286 A MA56286 A MA 56286A MA 56286 A MA56286 A MA 56286A MA 56286 B1 MA56286 B1 MA 56286B1
Authority
MA
Morocco
Prior art keywords
immunocytokine
protein complex
complex based
heterodimeric protein
agent
Prior art date
Application number
MA56286A
Other languages
English (en)
French (fr)
Other versions
MA56286A1 (fr
Inventor
Stanislav Rudolfovich Evdokimov
Andrei Borisovich Ulitin
Sergei Andreevich Ageev
Ivan Vladimirovich Mitroshin
Alekseyvladimirovich Kononov
Aleksandr Andreevich Gordeev
Elena Vladimirovna Vinogradova
Aleksandra Pavlovna Shmakova
Dmitryvalentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA56286A1 publication Critical patent/MA56286A1/fr
Publication of MA56286B1 publication Critical patent/MA56286B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA56286A 2019-09-19 2020-09-20 Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r? MA56286B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019129569A RU2753282C2 (ru) 2019-09-19 2019-09-19 ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
PCT/RU2020/050233 WO2021054867A1 (ru) 2019-09-19 2020-09-20 Иммуноцитокин, включающий гетеро димерный белковый комплекс на основе il-15 и il-15rα

Publications (2)

Publication Number Publication Date
MA56286A1 MA56286A1 (fr) 2023-05-31
MA56286B1 true MA56286B1 (fr) 2023-09-27

Family

ID=74873995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56286A MA56286B1 (fr) 2019-09-19 2020-09-20 Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r?

Country Status (21)

Country Link
US (1) US20230011234A1 (cg-RX-API-DMAC7.html)
EP (1) EP4032539A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022549276A (cg-RX-API-DMAC7.html)
KR (1) KR20220145323A (cg-RX-API-DMAC7.html)
CN (1) CN115297885A (cg-RX-API-DMAC7.html)
AR (1) AR120011A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020351560A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022005173A2 (cg-RX-API-DMAC7.html)
CA (1) CA3151780A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022003156A2 (cg-RX-API-DMAC7.html)
JO (1) JOP20220071A1 (cg-RX-API-DMAC7.html)
MA (1) MA56286B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022003306A (cg-RX-API-DMAC7.html)
PE (1) PE20220603A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550688A1 (cg-RX-API-DMAC7.html)
PY (1) PY2056649A (cg-RX-API-DMAC7.html)
RU (1) RU2753282C2 (cg-RX-API-DMAC7.html)
TW (1) TWI891660B (cg-RX-API-DMAC7.html)
UY (1) UY38889A (cg-RX-API-DMAC7.html)
WO (1) WO2021054867A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202203254B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
CN116178572B (zh) * 2022-02-28 2025-12-23 厦门柏慈生物科技有限公司 构建嵌合蛋白的嵌合区域、构建方法、嵌合蛋白及其应用
CN115141283A (zh) * 2022-03-10 2022-10-04 厦门柏慈生物科技有限公司 一种融合蛋白、制备方法及其应用
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
WO2025031274A1 (zh) * 2023-08-04 2025-02-13 深圳众格生物科技有限公司 Sushi结构域突变体、融合蛋白、药物组合物和用途
CN122295373A (zh) * 2023-12-28 2026-06-26 南通壹宸生物医药科技有限公司 融合抗体及其应用
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2026037415A1 (zh) * 2024-08-16 2026-02-19 北京清辉联诺生物科技有限责任公司 一种IL15/IL15Rα复合物及其在细胞疗法领域的应用
WO2026161860A1 (en) * 2025-01-27 2026-07-30 Kadmon Corporation, Llc Dosing of immunocytokines for cancer treatment

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DK0935607T3 (da) * 1996-08-16 2004-12-06 Harvard College Oplöselige monovalente og multivalente MHC klasse II-fusionsproteiner samt anvendelser deraf
BR9908082A (pt) * 1998-02-19 2000-10-31 Harvard College Proteìna de fusão do complexo de histocompatibilidade principal classe ii, conjugado dos domìnios de ligação do complexo de histocompatibilidade principal multimérico, processos para detectar células t tendo uma especificidade do complexo definido de mhc / peptìdeo, para conferir a um indivìduo imunidade adotiva a um complexo definido de mhc / peptìdeo, para estimular ou ativar as células t reativas a um complexo definido de mhc / peptìdeo, para seletivamente matar células t reativas a um complexo definido de mhc / peptìdeo, para tolerizar um indivìduo humano a um complexo definido de mhc / peptìdeo, e, ácido nucleico isolado
ES2387394T3 (es) * 1999-12-23 2012-09-21 Zymogenetics, Inc. Procedimiento de tratamiento de la inflamación
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP2388266B1 (en) * 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
KR20120107122A (ko) * 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体il−15可溶性融合分子並びにその製造及び使用方法
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CA2904805A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
SI3030575T1 (sl) 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
EP3093295B1 (en) * 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof
CA2953816C (en) * 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US10905743B2 (en) 2014-12-19 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Interleukin 15 protein complex
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
MX2019004681A (es) * 2016-10-21 2019-10-07 Altor Bioscience Corp Moleculas basadas en il-15 multimericas.
KR102625293B1 (ko) * 2017-03-06 2024-01-15 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
US20200306301A1 (en) * 2017-07-03 2020-10-01 Torque Therapeutics, Inc. Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof

Also Published As

Publication number Publication date
CN115297885A (zh) 2022-11-04
MX2022003306A (es) 2022-04-26
RU2019129569A3 (cg-RX-API-DMAC7.html) 2021-03-19
JP2025182218A (ja) 2025-12-12
ZA202203254B (en) 2025-10-29
MA56286A1 (fr) 2023-05-31
UY38889A (es) 2021-04-30
PH12022550688A1 (en) 2023-05-29
CA3151780A1 (en) 2021-03-25
RU2753282C2 (ru) 2021-08-12
KR20220145323A (ko) 2022-10-28
JP2022549276A (ja) 2022-11-24
CO2022003156A2 (es) 2022-04-19
PE20220603A1 (es) 2022-04-25
JOP20220071A1 (ar) 2022-03-17
EP4032539A1 (en) 2022-07-27
TWI891660B (zh) 2025-08-01
EP4032539A4 (en) 2023-09-13
RU2019129569A (ru) 2021-03-19
PY2056649A (es) 2021-06-17
US20230011234A1 (en) 2023-01-12
TW202124420A (zh) 2021-07-01
AU2020351560A1 (en) 2022-11-24
BR112022005173A2 (pt) 2022-08-16
AR120011A1 (es) 2022-01-26
WO2021054867A1 (ru) 2021-03-25

Similar Documents

Publication Publication Date Title
MA56286A1 (fr) Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r?
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
Gimenez-Rivera et al. Mast cells limit the exacerbation of chronic allergic contact dermatitis in response to repeated allergen exposure
TN2019000099A1 (en) Anti-lag-3 antibodies and compositions
MX2025006958A (es) Agonistas parciales de interleucina-2
EP1461081A4 (en) ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION
ATE364618T1 (de) Antikörper gegen das muc18-antigen
BRPI0415505A (pt) agente terapêutico para mesotelioma
EA200400312A1 (ru) АНТАГОНИСТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ hTNFSF13b ЧЕЛОВЕКА
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
DK1272515T3 (da) Immunregulator
WO2004078098A3 (en) Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA37777B1 (fr) Préparation pharmaceutique
EP3959241A4 (en) USE OF AN ANTI-CD19 ANTIBODY TO TREAT AN AUTOIMMUNE DISEASE
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
EE03697B1 (et) Interleukiin-1 retseptori antagonisti intratsellulaarne isovorm
FR3099695B1 (fr) Dispositif de maintien d’un instrument médical et installation comprenant un tel dispositif
MA45890A1 (fr) Composition pharmaceutique destinée à prévenir une dépendance aux opioïdes
PL400309A1 (pl) Kwasy nukleinowe, proteiny oraz przeciwciala BTL-II
FR3143975B1 (fr) Phytoecdysones pour leur utilisation dans le traitement de pathologies respiratoires inflammatoires
FR3125965B1 (fr) Conjugués anticorps-médicament
Mohyddin et al. A Comprative Study of Quranic & Non-Quranic Life